Evonetix Ltd
- Founded in: 2015
- Number of employees: 39
- Country: United Kingdom
- Website: evonetix.com
Which input provides your business model/core technology towards a bio-based economy?
We aim to sell an enabling technology to every lab, enabling the acceleration of synthetic biology applications globally and the generation of enabled products. These applications will address some of the worlds biggest problems that require a biological approach. We aim to sell the instrument and proprietary consumables to end users.
Which market/clients do you address and which short-term/long-term goals do you have?
Our long term goal is to have one of our platforms on every lab bench as DNA synthesis underpins many applications. We can serve a diverse audience of customers including academia, agbio, pharma and industry. In the meantime we are aiming to connect with potential users of the technology to understand the product attributes required for each of the different customer segments and to build a platform that addresses the current unmet needs in the synthetic biology market as a whole.
What makes your approach unique compared to other stakeholders in the field?
DNA synthesis underpins all applications in synthetic biology. We are developing a bench top DNA synthesizer which will accelerate the rate of rapid prototyping required to unlock the potential of bioengineering to tackle many of the worlds most intractable problems, including renewable and sustainable biofuels, feeding the growing population, new materials using renewable feedstocks and new medicines for healthcare . We have developed a unique solution that combines thermal control in a highly parallel format to enable the precise synthesis and assembly of long high fidelity DNA at scale in a rapid turnaround time. This enables customers to potentially create whole pathways of highly diverse combinatorial libraries to shortcut the process of screening for highly desirable proteins for many broad applications in Agribio, Pharma, Industry and Research. This is an agnostic platform that can accept any thermally labile chemistry including enzymatic for long DNA synthesis.
You can meet Evonetix Ltd at EFIB in Brussels on 30 September – 2 October 2019.